EA201591233A1 - Состав-депо для инъекций, включающий оптически активный толваптан, и способ его получения - Google Patents
Состав-депо для инъекций, включающий оптически активный толваптан, и способ его полученияInfo
- Publication number
- EA201591233A1 EA201591233A1 EA201591233A EA201591233A EA201591233A1 EA 201591233 A1 EA201591233 A1 EA 201591233A1 EA 201591233 A EA201591233 A EA 201591233A EA 201591233 A EA201591233 A EA 201591233A EA 201591233 A1 EA201591233 A1 EA 201591233A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- composition
- injection
- optically active
- obtaining
- tolvaptan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к составу для инъекций, предназначенному для внутримышечного или подкожного введения, который применяется для профилактики или лечения поликистозной болезни почек и который способен поддерживать терапевтически эффективные концентрации толваптана в крови в течение продолжительного периода времени, а также к способу получения этого состава. Более конкретно, настоящее изобретение относится к составу-депо для инъекций, включающему (1) частицы, содержащие оптически активный толваптан в качестве действующего ингредиента, и (2) фармацевтически приемлемый носитель для инъекций, а также к способу получения этого состава.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261747005P | 2012-12-28 | 2012-12-28 | |
PCT/JP2013/085355 WO2014104412A1 (en) | 2012-12-28 | 2013-12-27 | Injectable depot formulation comprising optically active tolvaptan and process of producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201591233A1 true EA201591233A1 (ru) | 2015-11-30 |
Family
ID=50097796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591233A EA201591233A1 (ru) | 2012-12-28 | 2013-12-27 | Состав-депо для инъекций, включающий оптически активный толваптан, и способ его получения |
Country Status (19)
Country | Link |
---|---|
US (1) | US9597283B2 (ru) |
EP (1) | EP2941242B1 (ru) |
JP (1) | JP6265999B2 (ru) |
KR (1) | KR20150102083A (ru) |
CN (1) | CN104902874A (ru) |
AR (1) | AR094291A1 (ru) |
AU (1) | AU2013366872A1 (ru) |
BR (1) | BR112015015439A2 (ru) |
CA (1) | CA2894516A1 (ru) |
EA (1) | EA201591233A1 (ru) |
HK (1) | HK1211225A1 (ru) |
IL (1) | IL239351A0 (ru) |
MX (1) | MX2015008220A (ru) |
NZ (1) | NZ630346A (ru) |
PH (1) | PH12015501373A1 (ru) |
SG (1) | SG11201504381VA (ru) |
TW (1) | TW201427669A (ru) |
WO (1) | WO2014104412A1 (ru) |
ZA (1) | ZA201504338B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI660748B (zh) * | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液 |
TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及/或治療多囊腎病之藥物 |
EP3452031A4 (en) * | 2016-05-05 | 2019-12-11 | Liquidia Technologies, Inc. | PRECISION-CONTROLLED LOADING AND RELEASE PARTICLES FOR POST-OPERATIONAL PAIN |
WO2018096560A1 (en) * | 2016-11-23 | 2018-05-31 | Cipla Limited | Long acting depot formulation for the continuous dopaminergic stimulation |
GB2561355A (en) * | 2017-04-10 | 2018-10-17 | Eaststone Ltd | Pharmaceutical composition and a method for manufacturing the same |
CN109528636B (zh) * | 2018-12-20 | 2022-05-03 | 常州市阳光药业有限公司 | 托伐普坦口服溶液及其制备方法 |
WO2020131680A1 (en) * | 2018-12-21 | 2020-06-25 | Resilio Therapeutics, LLC | Compounds and methods for the treatment of polycystic kidney disease (pkd) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985869A (en) | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
DK0450097T3 (da) | 1989-10-20 | 1996-05-20 | Otsuka Pharma Co Ltd | Benzoheterocykliske forbindelser |
US5753677A (en) | 1989-10-20 | 1998-05-19 | Otsuka Pharmaceutical Co., Ltd. | Benzoheterocyclic compounds |
US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
JPH04210355A (ja) | 1990-07-24 | 1992-07-31 | Ono Sokki Co Ltd | 加工装置 |
JP4210355B2 (ja) | 1997-07-03 | 2009-01-14 | 大塚製薬株式会社 | 固形製剤組成物 |
PL1968990T3 (pl) * | 2005-12-27 | 2015-06-30 | Otsuka Pharma Co Ltd | Rozpuszczalny w wodzie związek benzoazepinowy i jego kompozycja farmaceutyczna |
TWI459947B (zh) | 2007-06-26 | 2014-11-11 | Otsuka Pharma Co Ltd | 苯并氮呯化合物及藥學製劑 |
JP5590780B2 (ja) * | 2007-06-26 | 2014-09-17 | 大塚製薬株式会社 | 医薬 |
TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
-
2013
- 2013-12-27 WO PCT/JP2013/085355 patent/WO2014104412A1/en active Application Filing
- 2013-12-27 AR ARP130105041A patent/AR094291A1/es unknown
- 2013-12-27 SG SG11201504381VA patent/SG11201504381VA/en unknown
- 2013-12-27 MX MX2015008220A patent/MX2015008220A/es unknown
- 2013-12-27 US US14/758,108 patent/US9597283B2/en not_active Expired - Fee Related
- 2013-12-27 JP JP2015532202A patent/JP6265999B2/ja not_active Expired - Fee Related
- 2013-12-27 NZ NZ630346A patent/NZ630346A/en not_active IP Right Cessation
- 2013-12-27 BR BR112015015439A patent/BR112015015439A2/pt not_active IP Right Cessation
- 2013-12-27 EA EA201591233A patent/EA201591233A1/ru unknown
- 2013-12-27 AU AU2013366872A patent/AU2013366872A1/en not_active Abandoned
- 2013-12-27 KR KR1020157020124A patent/KR20150102083A/ko not_active Application Discontinuation
- 2013-12-27 CA CA2894516A patent/CA2894516A1/en not_active Abandoned
- 2013-12-27 EP EP13829043.2A patent/EP2941242B1/en active Active
- 2013-12-27 TW TW102148701A patent/TW201427669A/zh unknown
- 2013-12-27 CN CN201380068094.XA patent/CN104902874A/zh active Pending
-
2015
- 2015-06-11 IL IL239351A patent/IL239351A0/en unknown
- 2015-06-15 ZA ZA2015/04338A patent/ZA201504338B/en unknown
- 2015-06-17 PH PH12015501373A patent/PH12015501373A1/en unknown
- 2015-12-08 HK HK15112114.9A patent/HK1211225A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2894516A1 (en) | 2014-07-03 |
TW201427669A (zh) | 2014-07-16 |
EP2941242B1 (en) | 2017-02-01 |
BR112015015439A2 (pt) | 2017-07-11 |
JP6265999B2 (ja) | 2018-01-24 |
WO2014104412A1 (en) | 2014-07-03 |
SG11201504381VA (en) | 2015-07-30 |
NZ630346A (en) | 2016-06-24 |
ZA201504338B (en) | 2016-11-30 |
PH12015501373A1 (en) | 2015-09-07 |
HK1211225A1 (en) | 2016-05-20 |
IL239351A0 (en) | 2015-07-30 |
EP2941242A1 (en) | 2015-11-11 |
US9597283B2 (en) | 2017-03-21 |
CN104902874A (zh) | 2015-09-09 |
JP2016503753A (ja) | 2016-02-08 |
AR094291A1 (es) | 2015-07-22 |
US20150352041A1 (en) | 2015-12-10 |
KR20150102083A (ko) | 2015-09-04 |
MX2015008220A (es) | 2015-09-29 |
AU2013366872A1 (en) | 2015-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591233A1 (ru) | Состав-депо для инъекций, включающий оптически активный толваптан, и способ его получения | |
EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
EA201791727A1 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии | |
EA201500848A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ОБОГАЩЕННОЙ IgG-КОМПОЗИЦИИ ИЗ ПЛАЗМЫ | |
EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
EA201390840A1 (ru) | Полициклический lpaантагонист и его применение | |
EA201490103A1 (ru) | Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1 | |
EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
EA201301019A1 (ru) | Бензодиоксановые ингибиторы продуцирования лейкотриена | |
EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201101111A1 (ru) | Алкиламинозамещенные дицианопиридины и их пролекарства в виде сложных эфиров с аминокислотами | |
RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
EA201691790A1 (ru) | Способ получения продукта глатирамера ацетата | |
MX2019007779A (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). | |
EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
EA201590697A1 (ru) | Производные кетамина | |
EA201290517A1 (ru) | Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a | |
EA201591618A1 (ru) | Замещенные имидазопиридазины | |
EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
EA201491500A1 (ru) | Способы лечения фиброза | |
EA201490516A1 (ru) | Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ | |
EA201992832A1 (ru) | Подкожное введение adamts13 |